Stock GRANULES GRANULES INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Granules India Limited NSE India S.E.

Equities

GRANULES

INE101D01020

Delayed NSE India S.E.
Other stock markets
 10:52:44 13/05/2024 BST 		5-day change 1st Jan Change
404.8 INR +1.68% Intraday chart for Granules India Limited -4.33% -0.11%
04-30 Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares MT
04-15 Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares
Granules India Unit Gets VAI Status for Virginia Facility
Granules India Limited Announces Appointment of Directors
Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director
Granules India Limited Announces Appointment of Sethu Madhavan Sankaran as Senior Vice President - Api Manufacturing & Operations
Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer
Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing
Paracetamol maker Granules India posts marginal rise in Q3 profit
Granules India's Posts Gains in Fiscal Q3 Consolidated Net Profit
Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Granules Pharmaceuticals Unit's Virginia Facility Gets Five Observations from US FDA
Granules India Gets US FDA Nod for Pantoprazole Sodium Delayed-Release Tablets
Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets
Granules India Arm Gets US FDA Nod for Sildenafil for Oral Suspension
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand
Granules India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Granules India Gets US FDA's Approval for Generic Drug for GERD Symptoms
Granules India Limited Receives ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules
Indian paracetamol maker Valiant Laboratories lists at 16% premium
Granules India Gets US FDA Nod for Hypertension Treatment Drug
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRANULES Stock
  4. GRANULES Stock
  5. News Granules India Limited
  6. Other languages